Navigation Links
Ad hoc: Interim report about clinical trial of BF-200 ALA in,actinic keratosis

LEVERKUSEN, Germany, 30 April 2007 - Biofrontera AG announced that an interim report regarding the clinical study of BF-200 ALA in actinic keratosis was received today from an independent review committee. The objectives of the study are to investigate the efficacy and safety of several doses of BF-200 ALA in photodynamic therapy. The comments received today refer to the clinical results eight weeks after treatment. An additional report about the results after twelve weeks will follow.

The interim committee reported that no side effect justifying concerns about the safety of this dose were observed in any dose group. On the basis of the available data, the therapy was found to be safe for all doses tested.

In spite of the limited patient number, different doses gave rise to clear differences in efficacy. However, the results of the different doses were not yet disclosed. The committee announced this disclosure once it has received and analyzed the clinical results 12 weeks after treatment. Biofrontera expects this second report within few weeks.

To optimize the statistical study design, the committee has proposed to continue the phase III part of the study separately. This will enable the complete analysis of the 12-week data. On this basis, Biofrontera intends to continue the further development of the 10 % dose, provided this dose selection is supported by the 12-week data.

Biofrontera AG Hemmelrather Weg 201, 51377 Leverkusen, Germany ISIN: DE0006046113 WKN: 604611

Contact: Anke zur Mühlen Biofrontera AG Tel.: +49 (0214) 87 63 222 Fax.: +49 (0214) 87 63 290 e-mail: a.zurmuehlen@biofrontera.com


'"/>




Page: 1

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
3. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
4. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
5. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
6. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
7. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
8. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
9. Avalon Pharmaceuticals Announces Positive Interim Results For AVN944 Phase I Trial
10. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
11. Interim Data From RECORD Study Show No Significant Difference Between Avandia and Standard Therapy in Risk of Cardiovascular Hospitalization or Death
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: hoc Interim report about clinical trial ALA actinic keratosis
(Date:9/30/2014)... 30, 2014  Tasly Pharmaceuticals, Inc., the world,s ... announced today the launch of Deepure. ... address men and women concerned with supporting their ... old age while helping keep their health care ... and herb-based formulas, namely, ProHeart PLUS, ImmunoPower PLUS, ...
(Date:9/30/2014)... 2014  Decision Resources Group finds that the markets ... , Russia , ... (BRIC) will see robust expansion as these economies expand ... procedures. Although revenues will be somewhat impeded by poor ... approval times and demand for low-cost products, the market ...
(Date:9/30/2014)... --  Easy Breathe , the fastest growing online ... now offers the revolutionary AirSense CPAPs by ... apnea therapy devices with internal cellular modems.  This break-through ... share real-time data on each user,s quality of sleep ... addition, the internal modem allows the CPAP to be ...
Breaking Medicine Technology:Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 2Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 3Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 2Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 3Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 4
... startup  PhotOral™  announced today it has licensed a ... to develop a novel intraoral device that uses ... dental plaque microorganisms. The agreement empowers ... the $7 billion oral care market.  PhotOral Founder ...
... R.I., Dec. 15, 2011  CVS Caremark announced today ... Chain Distinction Award North America in the Logistics ... week at the annual Supply Chain Logistics Summit ... http://photos.prnewswire.com/prnh/20090226/NE75914LOGO ) The Logistics Best ...
Cached Medicine Technology:Life Sciences Startup PhotOral Licenses Patented Oral Blue-Light Technology From Forsyth Institute 2CVS Caremark Receives Logistics Best Practice Award at 2011 Supply Chain Logistics Summit 2CVS Caremark Receives Logistics Best Practice Award at 2011 Supply Chain Logistics Summit 3
(Date:9/30/2014)... Research by UC Irvine immunologists reveals new information ... a vital process that determines how the body,s ability ... of Nature Immunology , neurology professor Dr. Michael ... Immunology colleagues describe a critical mechanism underlying how T ... , A T cell is a type of blood ...
(Date:9/30/2014)... Vegas, NV (PRWEB) September 30, 2014 ... by Blue Star Nutraceuticals designed to help maximize lean, ... that optimizes the body’s absorption of glucose has caught ... , “The main purpose behind Glycodrive is to ... builds lean muscle,” reports Michaels. “Carbs are essential in ...
(Date:9/30/2014)... Elevate , the latest product from ... and out of the gym by providing natural ingredients that ... of Shane Michaels, prompting an investigative review. , “When ... most people simply just don’t have the ability to perform ... work, getting the motivation to finish a project, or even ...
(Date:9/30/2014)... For most families, fall means back-to-school pictures and ... annual festival. For millions of children, fall also means ... infection Enterovirus D68. , While symptoms mimic the ... especially children with weakened immune systems – can develop ... prompting hospitals across the country to enact visitor restrictions. ...
(Date:9/30/2014)... Regenerative Medicine Solutions (RMS) is set to open ... RMS welcomes the launch of an entirely new facility, ... new treatment center for the Lung Institute. , ... Nashville, the hope is to bring awareness to those ... undiagnosed. With Nashville being a hub for medical technology, ...
Breaking Medicine News(10 mins):Health News:UCI study uncovers important process for immune system development 2Health News:Glycodrive Review Exposes Blue Star Nutraceutical’s Supplement for Leaner, Stronger Muscles 2Health News:Elevate: Review Exposes Blue Star Nutraceutical’s Latest Supplement for Ultimate Brain Function, Focus, and Energy 2Health News:As Hospitals Combat Enterovirus Outbreaks, Patients and Families Turn to “Virtual Visits” with CaringBridge 2Health News:Regenerative Medicine Solutions Expanding 2
... , , BALTIMORE, ... groups and industry to educate expecting parents about the medical significance ... three out of every four pregnant women still consider themselves only ... on stem cell science and policy found that a proprietary, web-based ...
... ROCHESTER, N.Y., Sept. 23 Bausch & Lomb, the ... J. Palmisano have joined its board of directors. , , ... and relevant experience," said Gerald M. Ostrov, chairman and chief executive ... positioned for long-term growth. We welcome Kerry and Bob and look ...
... PLAINS, N.Y., SEPT. 23, 2009 -- Pregnant women should be ... the vaccines become available this year to protect them against ... to eight leading national maternal and infant health organizations. ... College of Obstetricians and Gynecologists, the American Academy of Pediatrics, ...
... Agent-based models (ABMs) are powerful computer-simulation modeling techniques ... of biological phenomena, such as tumor growth, the ... through a population. Researchers will gather Dec. ... Biological Synthesis (NIMBioS) on the University of Tennessee, ...
... , ... for November 17-19, 2009, in Miami, FL , ... Portland, Maine (PRWEB) September 23, 2009 -- IntertechPira and ... 2009, the industry,s leading event focusing on biotechnology, engineering and alternative energy applications as ...
... WAYNE, Pa., Sept. 23 RRY Publications announced the preliminary ... the premier gathering of stem cell company executives, scientists and ... The Summit is an intensive one-day event where attendees explore ... stem cell product commercialization, and the latest investment opportunities within ...
Cached Medicine News:Health News:Data Released at an International Stem Cell Meeting Highlights Effectiveness of New Patient Education System Developed to Support Federal and State Guidelines on Cord Blood Education 2Health News:Data Released at an International Stem Cell Meeting Highlights Effectiveness of New Patient Education System Developed to Support Federal and State Guidelines on Cord Blood Education 3Health News:R. Kerry Clark and Robert J. Palmisano Join Bausch & Lomb Board of Directors 2Health News:Pregnant women need flu shots 2Health News:Agenda Announced for Ionic Liquids 2009 2Health News:5th Annual Stem Cell Summit Set for Feb. 16 in New York City 2Health News:5th Annual Stem Cell Summit Set for Feb. 16 in New York City 3